Welcome to our dedicated page for Kailera Therapeutics SEC filings (Ticker: KLRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Kailera Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Kailera Therapeutics's regulatory disclosures and financial reporting.
Kailera Therapeutics, Inc. reported that officer Kathleen Tregoning received a grant of stock options covering 175,000 shares of common stock. The options have an exercise price of $23.30 per share and expire on July 6, 2036.
These options vest as to 25% of the underlying shares on June 29, 2027 and then in 36 substantially equal monthly installments, subject to her continued service. Following this grant, she holds stock options exercisable for 175,000 shares directly.
Kailera Therapeutics, Inc. executive Kathleen Tregoning has filed an initial Form 3, which is a required ownership report for company insiders. The filing lists her as an officer of the company with no stock transactions or holdings reported in this submission.
Kailera Therapeutics, Inc. CEO and President Ronald C. Renaud Jr. exercised stock options to acquire 38,094 shares of common stock at an exercise price of $5.25 per share on June 9, 2026. Following the transaction, he directly holds 38,094 common shares.
The exercised options covered 38,094 underlying shares out of a larger grant, with 817,826 stock options reported as remaining after the transaction and expiring on September 19, 2034. The options began vesting on September 9, 2025 and continue vesting in substantially equal monthly installments, conditioned on his continued service.
Kailera Therapeutics, Inc. reported a net loss of $78.9 million for the three months ended March 31, 2026, significantly higher than $18.0 million a year earlier as it ramped spending on obesity drug development.
Research and development expenses rose to $70.9 million, up from $10.1 million, driven by global Phase 3 trials for ribupatide injection and advancement of its oral GLP-1 programs. General and administrative costs increased to $13.8 million.
At March 31, 2026, Kailera held $581.9 million in cash, cash equivalents and marketable securities. Including $718.8 million of gross proceeds from its April 2026 IPO, the company believes it is funded into mid-2028 while progressing four clinical-stage obesity product candidates, supported by recent positive data from KAI-7535 and KAI-4729.
Kailera Therapeutics reported first-quarter 2026 results and detailed rapid progress across its obesity-focused pipeline. The company recorded a net loss of $78.9 million for the quarter, wider than $18.0 million a year earlier, as research and development spending grew to $70.9 million from $10.1 million with multiple new clinical trials underway.
As of March 31, 2026, Kailera had $581.9 million in cash, cash equivalents and marketable securities, and recently closed an initial public offering of 44,921,875 shares at $16.00 per share for gross proceeds of $718.8 million, which together are expected to fund operations into mid-2028. Clinically, oral ribupatide achieved up to 12.1% mean weight loss at Week 26 with 38.6% of participants losing at least 15% of body weight, while tri-agonist KAI-4729 showed up to 16.0% weight loss at Week 12 versus 5.4% with placebo.
BCLS Fund IV Investments, L.P., an affiliate of Bain Capital Life Sciences, filed a Schedule 13D reporting a significant stake in Kailera Therapeutics, Inc.. The fund beneficially owns 22,583,268 shares of common stock, representing about 17.4% of the outstanding shares.
The position comes from preferred stock converting one-for-one into common stock at Kailera’s initial public offering and the purchase of 1,562,500 shares at $16.00 per share for $25,000,000. BCLS indicates investment purposes, plans to work actively with management and the board, and holds registration and lock-up rights under an Investor Rights Agreement and a 180-day Lock-Up Agreement.
BCPE Perseus Investor, LP filed a Schedule 13D disclosing beneficial ownership of 26,255,581 shares of Kailera Therapeutics common stock, representing about 20.3% of the company. The stake comes from the conversion of 17,857,143 Series B preferred shares at IPO and an additional 8,398,438 shares bought from underwriters at $16.00 per share for $134,375,008, funded with its own capital.
The filing notes that Bain Capital-affiliated entities control the reporting person and that Bain partner Andrew Kaplan sits on Kailera’s board. BCPE Perseus describes its position as an investment and indicates it may increase or decrease its holdings over time. An Investor Rights Agreement grants demand, piggyback and Form S-3 registration rights, and a 180-day lock-up limits sales after the IPO prospectus date.
RTW Investments-managed funds, as ten percent owners of Kailera Therapeutics, reported increasing their indirect position in the company. On April 20, 2026, affiliated funds bought 500,000 shares of Common Stock in open-market transactions at $16.00 per share.
On the same date, all held Series A and Series B Preferred Stock automatically converted into Common Stock on a 1-for-1 basis for no additional consideration immediately before the closing of the initial public offering, adding 10,276,820 shares. After these conversions and purchases, the affiliated funds indirectly held 10,776,820 shares of Common Stock. The filing notes that RTW and Roderick Wong disclaim beneficial ownership except to the extent of their pecuniary interest.
Hengrui (USA) Ltd., a wholly owned subsidiary of Jiangsu Hengrui Pharmaceuticals Co., Ltd., converted its Series A-2 preferred holdings in Kailera Therapeutics into common stock. On the conversion date, 2,034,133 and 9,477,719 shares of common stock were received from Series A-2 convertible non-voting and Series A-2 convertible preferred stock, respectively, at a stated price of $0.0000 per share. The preferred shares automatically converted into common immediately before Kailera’s initial public offering, leaving no remaining Series A-2 preferred outstanding and establishing a large direct common-stock position, plus 1 share held indirectly by Hengrui (USA) Ltd.
Bain Capital–affiliated entities significantly increased their stake in Kailera Therapeutics, Inc. through BCPE Perseus Investor, LP. On April 20, 2026, BCPE Perseus reported an open-market purchase of 8,398,438 shares of Kailera common stock at $16.00 per share, bringing one reported indirect holding line to 26,255,581 shares.
On the same date, each share of Kailera’s Series B Preferred Stock automatically converted into common stock on a 1:1 basis upon the closing of Kailera’s initial public offering, resulting in 17,857,143 newly issued common shares and reducing the reported Series B Preferred Stock position to zero. All securities are held directly by BCPE Perseus, while Bain Capital Investors, LLC and related Bain Capital funds may be deemed to share voting and dispositive power but disclaim beneficial ownership except for their pecuniary interests.